165 related articles for article (PubMed ID: 34588590)
1. Using ex vivo culture to assess dynamic phenotype changes in human prostate macrophages following exposure to therapeutic drugs.
Boibessot C; Joncas FH; Park A; Berrehail Z; Pelletier JF; Gris T; Bergeron A; Toren P
Sci Rep; 2021 Sep; 11(1):19299. PubMed ID: 34588590
[TBL] [Abstract][Full Text] [Related]
2. Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
Ruan H; Bao L; Tao Z; Chen K
Cancer Immunol Res; 2021 Jul; 9(7):838-852. PubMed ID: 34011528
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
Wu WF; Wang L; Spetsieris N; Boukovala M; Efstathiou E; Brössner C; Warner M; Gustafsson JA
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33771918
[TBL] [Abstract][Full Text] [Related]
4. Microtubule-associated protein tau (MAPT) promotes bicalutamide resistance and is associated with survival in prostate cancer.
Sekino Y; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shiota M; Takeshima Y; Yasui W; Matsubara A
Urol Oncol; 2020 Oct; 38(10):795.e1-795.e8. PubMed ID: 32430253
[TBL] [Abstract][Full Text] [Related]
5. A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN; Beer TM; Alumkal JJ; Slottke RE; Redmond WL; Thomas GV; Thompson RF; Wood MA; Koguchi Y; Chen Y; Latour E; Bergan RC; Drake CG; Moran AE
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32616555
[TBL] [Abstract][Full Text] [Related]
6. Enzalutamide-induced and PTH1R-mediated TGFBR2 degradation in osteoblasts confers resistance in prostate cancer bone metastases.
Su S; Cao J; Meng X; Liu R; Vander Ark A; Woodford E; Zhang R; Stiver I; Zhang X; Madaj ZB; Bowman MJ; Wu Y; Xu HE; Chen B; Yu H; Li X
Cancer Lett; 2022 Jan; 525():170-178. PubMed ID: 34752846
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Hirayama Y; Tam T; Jian K; Andersen RJ; Sadar MD
Mol Oncol; 2020 Oct; 14(10):2455-2470. PubMed ID: 32734688
[TBL] [Abstract][Full Text] [Related]
9. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model.
Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ
Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.
Cioni B; Zaalberg A; van Beijnum JR; Melis MHM; van Burgsteden J; Muraro MJ; Hooijberg E; Peters D; Hofland I; Lubeck Y; de Jong J; Sanders J; Vivié J; van der Poel HG; de Boer JP; Griffioen AW; Zwart W; Bergman AM
Nat Commun; 2020 Sep; 11(1):4498. PubMed ID: 32908142
[TBL] [Abstract][Full Text] [Related]
11. Enzalutamide With Radiation Therapy for Intermediate-Risk Prostate Cancer: A Phase 2 Study.
Kaplan I; Bubley GJ; Bhatt RS; Taplin ME; Dowling S; Mahoney K; Werner E; Nguyen P
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1416-1422. PubMed ID: 33636278
[TBL] [Abstract][Full Text] [Related]
12. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer.
Armstrong CM; Liu C; Liu L; Yang JC; Lou W; Zhao R; Ning S; Lombard AP; Zhao J; D'Abronzo LS; Evans CP; Li PK; Gao AC
Clin Cancer Res; 2020 Nov; 26(22):6064-6074. PubMed ID: 32928794
[TBL] [Abstract][Full Text] [Related]
13. Enzalutamide, an Androgen Receptor Antagonist, Enhances Myeloid Cell-Mediated Immune Suppression and Tumor Progression.
Consiglio CR; Udartseva O; Ramsey KD; Bush C; Gollnick SO
Cancer Immunol Res; 2020 Sep; 8(9):1215-1227. PubMed ID: 32661092
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
15. Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer.
Staniszewska M; Fragoso Costa P; Eiber M; Klose JM; Wosniack J; Reis H; Szarvas T; Hadaschik B; Lückerath K; Herrmann K; Fendler WP; Iking J
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299051
[TBL] [Abstract][Full Text] [Related]
16. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer.
Wang C; Peng G; Huang H; Liu F; Kong DP; Dong KQ; Dai LH; Zhou Z; Wang KJ; Yang J; Cheng YQ; Gao X; Qu M; Wang HR; Zhu F; Tian QQ; Liu D; Cao L; Cui XG; Xu CL; Xu DF; Sun YH
Clin Cancer Res; 2018 Feb; 24(3):708-723. PubMed ID: 29191973
[No Abstract] [Full Text] [Related]
17. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C
Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
[TBL] [Abstract][Full Text] [Related]
19. TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures.
Sha K; Yeh S; Chang C; Nastiuk KL; Krolewski JJ
Oncotarget; 2015 Sep; 6(28):25726-40. PubMed ID: 26327448
[TBL] [Abstract][Full Text] [Related]
20. Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.
Pal SK; Moreira D; Won H; White SW; Duttagupta P; Lucia M; Jones J; Hsu J; Kortylewski M
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
